A mathematical model for the determination of the optimum value of the treatment threshold for a continuous risk factor

被引:7
作者
Cucherat, M [1 ]
Boissel, JP [1 ]
机构
[1] Univ Lyon 1, Hospices Civils Lyon, F-69365 Lyon, France
关键词
cost-effectiveness; decision modeling; hypercholesterolemia; hypertension; primary prevention;
D O I
10.1023/A:1007423730270
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Hypercholesterolemia or hypertension are continuous risk factors for coronary heart disease. When a preventive action is carried out against such a risk factor, it is necessary to specify a risk factor level value, named the treatment threshold, above which a subject should be treated. But a non-arbitrary determination of this threshold value is impossible from the epidemiological data. A method for the non-arbitrary determination of the treatment threshold value is presented, based upon mathematical modelling of the clinical and economics consequences of the prevention policy in the whole population. In a cost-effectiveness approach, the model was used to estimate the cost per coronary event prevented according to the threshold value for blood cholesterol. It was found that a minimum in this outcome proposed as the optimum treatment threshold. It is possible, from a public health point of view, to determine an optimum, non-arbitrary treatment threshold value in the prevention of coronary heart disease with cholesterol-lowering interventions. The model proposed here could be useful in decision making processes.
引用
收藏
页码:23 / 29
页数:7
相关论文
共 16 条
[1]   FENOFIBRATE - A REVIEW OF ITS PHARMACODYNAMIC AND PHARMACOKINETIC PROPERTIES AND THERAPEUTIC USE IN DYSLIPIDEMIA [J].
BALFOUR, JA ;
MCTAVISH, D ;
HEEL, RC .
DRUGS, 1990, 40 (02) :260-290
[2]  
BERNSTEIN MJ, 1985, JAMA-J AM MED ASSOC, V253, P2080
[3]   SURROGATE END-POINTS - A BASIS FOR A RATIONAL APPROACH [J].
BOISSEL, JP ;
COLLET, JP ;
MOLEUR, P ;
HAUGH, M .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1992, 43 (03) :235-244
[4]  
BOISSEL JP, 1990, CORONARY CEREBROVASC, P240
[5]   BLOOD-PRESSURE, STROKE, AND CORONARY HEART-DISEASE .2. SHORT-TERM REDUCTIONS IN BLOOD-PRESSURE - OVERVIEW OF RANDOMIZED DRUG TRIALS IN THEIR EPIDEMIOLOGIC CONTEXT [J].
COLLINS, R ;
PETO, R ;
MACMAHON, S ;
HEBERT, P ;
FIEBACH, NH ;
EBERLEIN, KA ;
GODWIN, J ;
QIZILBASH, N ;
TAYLOR, JO ;
HENNEKENS, CH .
LANCET, 1990, 335 (8693) :827-838
[6]  
DOUSTEBLAZY P, 1988, ACTA MED SCAND, P137
[7]  
DOUSTEBLAZY P, 1988, REV EPIDEMIOL SANTE, V36, P342
[8]  
DUCIMETIERE P, 1980, LANCET, V1, P1346
[9]   AN ANALYSIS OF RANDOMIZED TRIALS EVALUATING THE EFFECT OF CHOLESTEROL REDUCTION ON TOTAL MORTALITY AND CORONARY HEART-DISEASE INCIDENCE [J].
HOLME, I .
CIRCULATION, 1990, 82 (06) :1916-1924
[10]  
LEWIS B, 1987, EUR HEART J, V8, P77